Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 158,000 KRW
Change Today +20,500 / 14.91%
Volume 1.7M
008930 On Other Exchanges
Korea SE
As of 2:29 AM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

hanmi science co ltd (008930) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/2/15 - 173,500
52 Week Low
08/8/14 - 12,429
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HANMI SCIENCE CO LTD (008930)

Related News

No related news articles were found.

hanmi science co ltd (008930) Related Businessweek News

No Related Businessweek News Found

hanmi science co ltd (008930) Details

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. The company offers prescription drugs in the areas of antidepressant, NSAIDs, neuropathic pain, obesity, epilepsy, lactobacillus intestinal supplement, oral care, hair growth, anti-inflammatory, schizophrenia, CNS, cough, smoking cessation aid, diabetes, total parenteral nutrition, osteoporosis, antiemetic, vaginal contraceptive, expectorants, ophthalmic, immunosuppressant, prostatism, urinogenital, cancer, antitussives, vitamins and nutritional supplements, constipation, dermatology, Parkinson's Disease, hepatitis, antibiotics, gastrointestinal, cardiovascular, and muscle relaxation. It also offers OTC drugs, including NSAID, oral care, myalgia, sinus cold, antitussives, ophthalmic, gum disease prevention, antihistamines, and hypnotics drugs, as well as calcium supplements, iron supplements, vitamins, and nutritional supplements. In addition, the company offers active pharmaceutical ingredients (APIs), including sterile cephalosporin, oral cephalosporin, and general APIs. It offers its products in various forms, such as tablets, capsules, and oral suspensions. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March, 2012. Hanmi Science Co., Ltd. was founded in 1973 and is headquartered in Seoul, South Korea.

Founded in 1973

hanmi science co ltd (008930) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hanmi science co ltd (008930) Key Developments

Eli Lilly and Company Signs Licensing and Collaboration Agreement with Hanmi Pharmaceutical

Eli Lilly and Company has entered into a licensing and collaboration agreement with Hanmi Pharmaceutical Co., Ltd. for the development and commercialization of Hanmi's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of autoimmune and other diseases. Under the terms of the agreement, Lilly will receive worldwide rights to the molecule for all indications excluding China, Hong Kong, Taiwan and Korea. Lilly will take development, regulatory, manufacturing, and commercial leadership for the molecule in the Lilly territories. Hanmi will receive an initial payment of $50 million and is eligible for up to $640 million in potential development, regulatory, and sales milestones. If the BTK inhibitor is successfully commercialized, Hanmi would also be eligible for tiered double-digit royalty payments.

Hanmi Out-Licenses Poziotinib, Promising, Irreversible, Pan-erbB Inhibitor Being Investigated for Treatment of Cancer, to Spectrum Pharmaceuticals

Hanmi pharmaceutical announced it has entered into a licensing agreement with Spectrum Pharmaceuticals for Poziotinib, a drug being investigated for the treatment of cancer. Poziotinib (HM781-36B) is a novel, oral, quinazoline-based pan-erbB inhibitor that irreversibly blocks signaling through the erbB family of tyrosine-kinase receptors including erbB1 (EGFR; HER1), erbB2 (HER2), and erbB4 (HER4), as well as erbB receptor mutations; this, in turn, leads to inhibition of the proliferation of tumor cells that overexpress these receptors. Mutations or overexpression/amplification of erbB family receptors have been associated with a number of different cancers, including non-small cell lung cancer (NSCLC), breast cancer, gastric cancer, etc. Currently, poziotinib is being investigated by Hanmi in erbB1-mutant NSCLC (Phase 2, sponsored by National OncoVenture), gastric cancer (Phase 2), head & neck cancer (Phase 2) and erbB2 positive breast cancer (Phase 2, sponsored by National OncoVenture). National OncoVenture is a funding initiative by the Korean government's National Cancer Center. Under the terms of the agreement, Spectrum received exclusive license to develop, manufacture and commercialize worldwide excluding Korea and China. Hanmi shall remain responsible for the cost of the ongoing Phase 2 studies through completion.

Hanmi Science Co., Ltd., Annual General Meeting, Mar 13, 2015

Hanmi Science Co., Ltd., Annual General Meeting, Mar 13, 2015., at 09:30 Korea Standard Time. Location: 14, Songpa-gu. Agenda: To consider the approval group financial statements; to consider the appointment of audit; to consider the approval of director remuneration; and to consider the approval of remuneration.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
008930:KS 158,000.00 KRW +20,500

008930 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 008930.
View Industry Companies

Industry Analysis


Industry Average

Valuation 008930 Industry Range
Price/Earnings 100.0x
Price/Sales 12.8x
Price/Book 17.0x
Price/Cash Flow 265.6x
TEV/Sales 13.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HANMI SCIENCE CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at